Based on this platform, we screened and identified Sunitinib as selectively inhibiting SHP2-mutant leukemia cells in vitro and in mouse models, offering promising prospects as a new effective treatment strategy for SHP2-mutant JMML in the future [26]. The gene discussed is PTPN11; the disease is juvenile myelomonocytic leukemia.